Brian Mansfield

Brian Mansfield

Company: Foundation for Fighting Blindness

Job title: Executive Vice President, Research & Chief Scientific Officer


Dr. Mansfield joined the Foundation in 2011. He is responsible for formulating and implementing the Foundation’s scientific strategy. The urgent mission of the Foundation is to develop treatments and cures for people affected with inherited retinal diseases. These represent a spectrum of 20 orphan indications such as retinitis pigmentosa, Stargardt disease and Usher syndrome, as well as genetically driven forms of age-related macular degeneration, that can result in blindness. Mansfield works with researchers in academia, small and large industry, and venture capital to accelerate translational research towards human proof of concept studies. In 2013 he established My Retina Tracker® Registry, an international, online registry for people with an inherited retinal disease. The registry data, capturing a person’s subjective experience of their disease, coupled to their clinician’s objective perspective is shared widely to facilitate research, clinical trial enrollment, and increased understanding of the prevalence and genetic heterogeneity of the diseases. Since 2017 the registry has offered a genetic testing program providing affected individuals with a no cost comprehensive gene panel test for the inherited retinal diseases, with over 7,500 people tested to date. Prior to joining the Foundation, Mansfield was the chief scientist and vice president for research and development for Correlogic Systems Inc., a senior scientist in protein development at Human Genome Sciences Inc., a tenured professor of eukaryotic genetics at Massey University, New Zealand, and a visiting professor at Georgetown University, Washington D.C.  Mansfield received an honors degree in physical chemistry from Canterbury University; a PhD in biochemistry from the University of Otago, New Zealand; and postdoctoral training in molecular genetics at the Johns Hopkins University School of Medicine. For over 25 years Mansfield has also held a position as an adjunct scientist at NICHD, NIH, as a member of the team who developed a gene therapy for glycogen storage disease type Ia that is currently in phase I/II clinical trials. He has over 85 peer-reviewed publications and holds multiple patents.


Implementing a Patient Registry to Accelerate Gene Therapy Development 4:00 pm

Developing a registry for retinal diseases – how it works Exploring the need for open access genetic testing to accelerate patient diagnosis and identification Supporting clinical trial recruitment by efficiently finding interested partiesRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.